A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001

To Learn More Call
201-510-0910

A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination with Nivolumab in Advanced Solid Tumors

Type of Cancer
Solid Tumor

Sponsor
Bristol Myers Squibb

Protocol Number
CA 090-001